Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial

Susan van Dieren, Sebastien Czernichow, J Chalmers, Andre-Pascal Kengne, Bastiaan E de Galan, Neil R Poulter, Mark Woodward, Joline W J Beulens, D E Grobbee, Yvonne T van der Schouw, Sophia Zoungas

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)


Aims: To determine the baseline characteristics and glucose-lowering therapies associated with weight change among patients with type 2 diabetes. Methods: Eleven thousand one hundred and forty participants in the ADVANCE trial were randomly assigned to an intensive [aiming for a haemoglobin A1c (HbA1c) =6.5 or a standard blood glucose-control strategy. Weight was measured at baseline and every 6 months over a median follow-up of 5 years. Multivariable linear regression and linear-mixed effect models were used to examine predictors of weight change. Results: The mean difference in weight between the intensive and standard glucose-control arm during follow-up was 0.75 kg (95 CI: 0.56-0.94), p-value
Original languageEnglish
Pages (from-to)464 - 469
Number of pages6
JournalDiabetes, Obesity and Metabolism
Issue number5
Publication statusPublished - 2012

Cite this